Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol

Joris Mallard1,2†, Elyse Hucteau1,2†, Roland Schott1, Thierry Petit1, Martin Demarchi1, Christine Belletier1, Meher Ben Abdelghani1, Hélène Carinato1, Pascale Chiappa1, Cathie Fischbach1, Michal Kalish-Weindling1, Audren Bousinière1, Stéphane Dufour2, Fabrice Favret3, Xavier Pivot1, Thomas J. Hureau2† and Allan F. Pagano2‡

† These authors have contributed equally to this work

Open Access

Edited by:
Yun Dai,
Peking University First Hospital, China

Reviewed by:
Antonio Macciò,
Ospedale Oncologico Armando Businco, Italy
Moritz Schumann,
German Sport University Cologne, Germany

*Correspondence:
Allan F. Pagano
allan.pagano@unistra.fr

1 Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France, 2 EA 3072: Mitochondria, Oxidative Stress and Muscular Protection Laboratory, Faculty of Medicine, Faculty of Sports Sciences, University of Strasbourg, Strasbourg, France

Background: Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients' physical status and exercise tolerance and, most importantly, their evolution throughout cancer treatment may represent the first step in efficiently counteracting their development with prescribed and tailored exercise training. In this context, the aim of the PROTECT-01 study will be to investigate the evolution of physical status, from diagnosis to the end of first-line treatment, of patients with one of the three most common cancers (i.e., lung, breast, and colorectal).

Methods: The PROTECT-01 cohort study will include 300 patients equally divided between lung, breast and colorectal cancer. Patients will perform a series of assessments at three visits throughout the treatment: (1) between the date of diagnosis and the start of treatment, (2) 8 weeks after the start of treatment, and (3) after the completion of first-line treatment or at the 6-months mark, whichever occurs first. For each of the three visits, subjective and objective fatigue, maximal voluntary force, body composition, cachexia, physical activity level, quality of life, respiratory function, overall physical performance, and exercise tolerance will be assessed.

Discussion: The present study is aimed at identifying the nature and severity of maladaptation related to exercise intolerance in the three most common cancers. Therefore, our results should contribute to the delineation of the needs of each group of patients and to the determination of the most valuable exercise interventions in order to counteract these maladaptations. This descriptive and comprehensive approach is a prerequisite in order to elaborate, through future interventional research projects, tailored exercise strategies to counteract specific symptoms that are potentially cancer type-dependent and, in fine, to improve the health and quality of life of cancer patients. Moreover, our concomitant focus on fatigue and cachexia will provide...
INTRODUCTION
Hallmark symptoms in patients with cancer include exacerbated fatigue (1, 2) and muscle wasting (3, 4) which impair their quality of life (2, 5, 6). Importantly, these are due to both the disease and the antineoplastic treatments (2, 4, 6–8), resulting in substantial differences across cancer types (3, 8–12). The characterization of these key parameters and, most importantly, their evolution throughout cancer treatment may represent the first step in finding ways of efficiently counteracting their development.

Cancer-related fatigue (CRF) is considered the main symptom in cancer patients and can be defined by clinicians as a chronic sensation of tiredness that is not fully reversed by rest, unlike common fatigue experienced by healthy individuals (1, 2), and is assessed subjectively with questionnaires. Moreover, as a multi-factorial symptom, CRF is also documented by objective measurements of neuromuscular fatigue, such as changes in force output (13). Previous studies report that 60–96% of cancer patients experience CRF (1, 4), a symptom that persists even after treatments conclude (8, 15). As a consequence, daily activities are affected (16) and physical activity levels are largely decreased (17, 18), affecting, in turn, skeletal muscle mass and function.

Skeletal muscle plays a major function in daily activity and possesses the ability to adapt according to applied stresses. This characteristic plasticity expresses itself through both structural and metabolic adaptations, and it is well-known that a decrease in muscle activity will lead to muscle deconditioning (19–23). In the context of cancer patients, the combination of a decrease in muscle mass and strength, an increase in fatigue, and a perturbation of identified biomarkers (i.e., inflammation, albumin, and hemoglobin) is known as cachexia (3, 24–26). It is a multifactorial syndrome characterized by ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support, leading to progressive functional impairment (4). Cachexia is considered a major public health problem and another important symptom in cancer patients (27). Indeed, a high level of cachexia is known to be associated with poor quality of life (6), reduced survivability (28), and massive public health costs (29). Cachexia also negatively impacts both perceived and/or objective CRF (5, 30–32), thus placing cancer patients in the center of a vicious cycle with fatigue inducing cachexia and cachexia inducing fatigue (Figure 1). This cachexia–fatigue vicious cycle suggests a strong interconnection between CRF and cachexia.

Exercise interventions have been investigated for improving CRF in many studies (33), with positive effects and a widespread agreement that they represent some of the most efficient interventions in cancer patients (34, 35). Exercise interventions also appear to be the best interventions to counteract cachexia specifically (36–38). For example, several studies have shown that exercise interventions in cancer patients are able to increase anti-inflammatory cytokine expression (IL-10, IL-15) and therefore decrease systemic pro-inflammatory factors (TNF-α, IL-6) responsible, at least in part, for the unbalanced protein turnover signaling and muscle deconditioning observed in this population (36–38). Today, exercise interventions are increasingly being recognized as an efficient strategy in counteracting both CRF and cachexia in cancer patients. Indeed, the implementation of supportive care with adapted physical activity in cancer patients is part of current and future political recommendations in France (39, 40) and elsewhere (41–43).

However, despite a great number of studies showing the positive effects of exercise interventions on many different health parameters (44–46); the literature also highlights the significant variability of patient adaptation to exercise programs (33, 47, 48). This variability appears to be accountable for the lack of tailored exercise interventions (49) and occurs due to the large number of parameters that influence the effects of exercise prescribed to patients: the type and stage of cancer, the type of treatment, and the physical status at the time of diagnosis. For example, lung cancer patients present a higher risk of cachexia, whereas breast cancer patients present a higher risk of heart

FIGURE 1 | Illustration of the theoretical cachexia–fatigue vicious cycle.
TABLE 1 | Inclusion and exclusion criteria.

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| First-line cancer treatment | Psychiatric, musculoskeletal, or neurological disorders |
| Breast cancer, Stage II or III, treated by taxane-based CT | Pregnant or nursing women |
| Colorectal cancer, stage IV, treated by CT, RT, IT, or TT | |
| Non-small cell lung cancer, stage III or IV, treated by CT, RT, IT, or TT | |
| Age ≥ 18 years | |
| Performance status WHO 0–2 | |
| Life expectancy > 6 months | |
| Ability to speak, understand and read French | |
| No contraindication to physical assessments | |
| Affiliate to social security system | |
| Give written informed consent | |

CT, chemotherapy; IT, immunotherapy; RT, radiation therapy; TT, targeted therapy; WHO, World Health Organization performance status.

failure (9, 50). All these different parameters, and their evolution throughout treatment, should be considered in prescribing the best exercise strategies on an individual basis, as opposed to generic exercise programs.

In this context, the aim of our study will be to describe, in cancer patients, the evolution of their physical status from diagnosis until the end of first-line treatment. This prospective cohort study will include patients with lung, colorectal, and breast cancer as they represent ~30% of all newly diagnosed cancers (51).

MATERIALS AND METHODS

Study Population

As they represent ~30% of all newly diagnosed cancers (51), this cohort study will focus on three different cancer types: breast, lung, and colorectal. The detailed inclusion and exclusion criteria are summarized in Table 1.

Patients newly diagnosed with cancer by an oncologist and satisfying inclusion and exclusion criteria described in Table 1 will be informed of the study protocol. If interested, the patient will contact one of the study coordinators for full information about the study as well as to discuss any questions pertaining to it. Once the patient has provided the written consent form to participate in this study, the visits will be scheduled.

Study Design

This cohort study aims to investigate the evolution of physical status from diagnosis to the end of first-line treatment. Therefore, after signing the written consent form, three visits will be scheduled. All assessments, detailed hereafter, will be performed at inclusion (Visit 1, between the time of diagnosis and the beginning of the treatment), 8 weeks after the beginning of the treatment (Visit 2), and either during the week after completion of first-line treatment or at the 6-months mark (Visit 3), whichever occurs first. The PROTECT-01 enrolment time is 18 months, and the study design is detailed in Figure 2.

Study Assessments

In order to assess the evolution of our different measurements throughout cancer treatment, all assessments will be performed via the same methods and under the same conditions across the three visits. All of the assessments will be performed chronologically in the order that they appear in the description provided hereafter. All parameters analyzed in this study are displayed in Table 2.

Clinical Data

Age, gender, tobacco consumption, significant health history (e.g., disease, surgery), type of cancer, and date of diagnosis will be collected via the medical file at the first visit. The presence of metastases and their sites, type of treatment (chemotherapy, immunotherapy, targeted therapy, radiotherapy) for lung and colorectal cancer patients, disease stage, performance status WHO, and significant concomitant treatments (e.g., corticosteroids, analgesics, antidepressants, antihypertensives) will also be collected and tracked throughout the study.

Questionnaires

Perceived cancer-related fatigue will be reflected by the score of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) scale version 4 (52). The FACIT-F is a subscale of the FACIT scales, a collection of health-related quality of life questionnaires targeted to the management of chronic illness. Patients will answer a 13-item scale to report their fatigue and its impact on their daily life during the previous week. Items
are rated on a 0–4 intensity scale (0: not at all, 1: a little bit, 2: somewhat, 3: quite a bit, 4: very much). After performing reversal scores for appropriate items, scores will be analyzed through two specific subscales (health-related quality of life and fatigue) and the global score obtained from the FACIT-F, where higher scores indicate less fatigue or better functioning.

Physical activity level will be assessed using the 16-item Global Physical Activity Questionnaire version 2 (GPAQ-2) (53). GPAQ-2 collects information on sedentary behavior and physical activity in three domains: (1) activity at work, (2) travel to and from places, and (3) recreational activities during a typical week. Patient engagement in moderate and vigorous physical activity level is assessed based on dichotomous response (i.e., “yes” or “no”). Intensity of activities are classified using MET (Metabolic Equivalent of Task) as follows: inactivity (1 MET), moderate (4 METs), and vigorous (8 METs). For patients performing moderate and/or vigorous activities, they will also have to report their frequency (number of days per week) and duration. Then, a score will be calculated based on the characteristics (i.e., MET, frequency, and duration) of activities in the moderate and vigorous domains. The higher the score, the better the patient’s physical activity level.

Quality of life will be evaluated by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (EORTC QLQ-C30), version 3, with 30 items (54). The self-administered EORTC QLQ-C30 is specifically designed for cancer patients, and version 3 is intended for all patients with cancer regardless of tumor site. The questionnaire includes five functioning scales (physical, role, cognitive, emotional, and social functioning) and three symptom scales (fatigue, pain, and nausea/vomiting). Additional cancer symptoms (dyspnea, sleep disturbance, loss of appetite, diarrhea, and constipation) and financial difficulties due to cancer and treatments are also reported by separate items. Patients will score intensity of symptoms during the past week for each item on a scale of 1–4 (1: not at all, 2: a little, 3: quite a bit, 4: very much). Patient overall global health and quality of life will be assessed, ranging from 1 to 7 (1 for very poor to 7 for excellent). A total score between 0 and 100 will be calculated for each scale. For global and functioning scales, a higher score is considered better, while for symptom scales a lower score is better.

**Body Composition and Cachexia**

Body mass and composition analyses will be performed using a bioelectrical impedance meter (SECA mBCA 515, SECA, Hamburg, Germany), validated in comparison to different robust methods assessing body composition, such as air-displacement plethysmography, dual-energy X-ray absorptiometry, and deuterium dilution (55). The bioelectrical impedance meter is also regularly used in studies investigating body composition in cancer patients (56–59). We will quantify body mass, fat free mass, fat mass, skeletal muscle mass, visceral fat, and body water repartition. Patient height will be measured to calculate body mass index (BMI, body mass/height2).

In accordance with Fearon et al. (4), cachexia will be diagnosed using fat-free mass index cut-off (i.e., <14.6 kg/m² for men and <11.4 kg/m² for women) assessed by a bioelectrical impedance meter (4). Furthermore, the severity of the cancer-related body mass loss (i.e., cachexia) will be investigated using the Martin score (28) at the second and third visit. Martin score is a robust grading system incorporating the independent prognostic significance of both BMI and percentage of body mass loss based on a correlation matrix from a cohort of more than 8,000 cancer patients (28). A severity stage of body mass loss between 0 and 4 is attributed to each patient according to their BMI at cancer diagnosis (28), with stage 0 being the lowest severity stage of cachexia, and stage 4, the highest. Importantly, each score is associated with a specific cumulative survival curve: the lower the score, the greater the survival probability (28).

**Respiratory Function**

Respiratory function will be assessed using a portable spirometer (USB Electronique Portable Spirobank II Smart MR, Rome, Italy). Patients will have to take maximum inspiration and blow to maximum exhalation. The mouthpiece on the device will be changed between each patient. The measured parameters will be:

### Table 2: Study time points.

| Visit 1 | Visit 2 | Visit 3 |
|---------|---------|---------|
| 1st | 2nd | 3rd |
| Inclusion criteria check-up | X | X | X |
| Informed consent | X | X | X |
| **Clinical data** | | | |
| Participant information | X | X | X |
| Disease history | X | X | X |
| Cancer record | X | X | X |
| Cancer treatment | X | X | X |
| Performance status WHO | X | X | X |
| Concurrent treatments | X | X | X |
| **Questionnaires** | | | |
| FACIT-F | X | X | X |
| GPAQ | X | X | X |
| EORTC QLQ-C30 | X | X | X |
| **Physical assessments** | | | |
| Body composition | X | X | X |
| Cachexia | X | X | X |
| Respiratory function | X | X | X |
| Maximal voluntary force | X | X | X |
| Fatigability | X | X | X |
| Physical performance | X | X | X |
| Exercise tolerance | X | X | X |

Visit 1, between the time of diagnosis and the beginning of the treatment; Visit 2, 8 weeks after the beginning of the treatment; Visit 3, at the end of first-line treatment or at the 6-months mark; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; FACIT-F, Functional Assessment of Chronic Illness Therapy—Fatigue; GPAQ, Global Physical Activity Questionnaire; WHO, World Health Organization performance status.
forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), Tiffeneau index or FEV1% (FEV1/FVC), peak expiratory flow (PEF), mean forced expiratory flow between 25 and 75% of FVC (FEF 25–75%), inspiratory vital capacity (IVC), expiratory vital capacity (EVC), inspiratory capacity (IC), expiratory reserve volume (ERV), and tidal volume (TV).

Maximal Voluntary Force
Finger flexors force will be measured using a handgrip dynamometer (Takei, TK200, Takei Scientific Instruments, Tokyo, Japan). Patients will sit upright in a chair with their feet touching the ground. The dominant arm will be placed with the elbow flexed at 90° on a table, while the forearm and the hand will be placed in a neutral position (Figure 3A). The non-dominant arm will be relaxed in a neutral position. For standardization, grip settings will be set at 5.1 cm (Figure 3A), corresponding to the standard position for grip testing (60, 61). Knee extensors force will be measured with a force transducer (Force sensor kit, Chronojump, Barcelona, Spain) positioned on a leg extension device (ProForma—Bodytone Evolution Extensions, Barcelona, Spain) (Figure 3B). Patients will be assessed in a seated position with the hip and knee joints fixed at 100 and 90°, respectively (where 180° represents a full knee extension), and aligned in the frontal axis. The lower leg will be attached with a non-compliant strap right above the malleoli. All participants will be familiarized with the maximal voluntary isometric contractions until the observation of a force plateau, indicating the ability to maintain the maximal contraction over 3 s and consistent peak values (≤3% difference) between trials. After a standardized warm-up (three contractions at 25, 50, and 75% of the estimated maximal voluntary contraction [MVC] torque), patients will be asked to perform three 3-s maximal voluntary isometric contractions under verbal encouragement. A 30-s rest period will be given between each MVC. The maximal value measured during the three trials will be used for further analysis.

Fatigability
Patients will be placed in the same position as the maximal voluntary force assessment. For both finger flexors and knee extensors, fatigability will be assessed by performing ten 3-s maximal voluntary isometric contractions under verbal encouragement with a 2-s rest period between each contraction. Fatigability will be calculated as the percent difference in peak force between the first and the last contraction (62).
Physical Performance
Physical performance will be assessed using the Short Physical Performance Battery (SPPB), a validated and reproducible test (interclass correlation coefficient of 0.86), indicating the risk of skeletal muscle force and mass loss in older adults (i.e., sarcopenia) (19, 63, 64). The SPPB test includes balance tests (joint feet, semi-tandem feet, and tandem feet), a 4-m walking speed test, and a 5-times-sit-to-stand test. For the balance tests, patients will be timed over a 10-s period and stopped if they lose their balance during this time. For the walking speed test, patients will have to walk spontaneously over 4 m, two times, and the fastest trial, in m·s⁻¹, will be used for further analysis. For the 5-times-sit-to-stand test, a chair (height, 43–45 cm; depth, 47.5 cm) will be used. With their arms crossed over their chest, patients will have to sit and stand five times as fast as possible on two different trials. Here again, the best performance will be used for analysis.

Exercise Tolerance
Exercise tolerance will be assessed using the classical 6-min walking test (6-MWT), following the American Thoracic Society (ATS) Statement recommendations (65). The 6-MWT is a validated and reproducible test (interclass correlation coefficient of 0.85), associated with mortality in cancer patients (66, 67). Patients will walk in a covered, flat, straight, well-delineated (marked every 3 m) and with no disturbance, 20-m corridor. A starting line will be marked, and two cones will represent the location of the U-turns. Physiological measurements (mean arterial pressure, oxygen saturation, and heart rate) will be performed at rest, at least 10 min before the beginning of the test, and again immediately at the end of the 6-MWT. Instructions will systematically be given to the patient as recommended in the ATS Statement (65). The total distance covered during the test (in meters) will be used to assess exercise tolerance.

Sample Size
An a priori sample size estimation was performed using the following sample size calculation formula (68):

\[
Sample\; size = \frac{Z_{\alpha/2}^2 \cdot SD^2}{\beta^2}
\]

Where: \(Z_{\alpha/2}\) is a standard normal variate (at 5% type 1 error i.e., \(P < 0.05\), it is 1.96); \(SD\) is the standard deviation of the main variable based on previous study; and \(d\) is the absolute error or precision based on previous study.

The primary outcome of this study is to investigate the evolution of exercise tolerance using the 6-MWT distance. According to Granger et al. (69), a 9.5% decline in the walking distance (i.e., exercise performance) during the 6-MWT test is sufficient to show a clinical decrease in exercise tolerance. Thus, based on the evolution of 6-MWT distances between the first and the second visit in our study, the hypothesis was that cancer patients will reduce, by at least 9.5%, their 6-MWT performance, and thus exhibit signs of exercise intolerance. We also determined the expected baseline 6-MWT results (659 ± 62 m) from the results observed in a healthy subjects group aged 55–75 years old (70), and a 7-m precision was calculated according to a test-retest reliability performed by Demers et al. (67). Using an \(\alpha\) level of 0.05 and a power (1-\(\beta\)) of 0.95, the total sample size was calculated as follows:

\[
Sample\; size = \frac{1.96^2 \cdot (62)^2}{7^2} = 301
\]

Our sample (\(n = 301\)) will be equally divided into our three groups of interest: 100 lung cancer patients, 100 breast cancer patients, and 100 colorectal cancer patients.

Statistical Analysis
Normality and variance homogeneity will be investigated on all collected data using the Shapiro-Wilk test and the Levene test, respectively. Appropriate parametric or non-parametric analyses will then be performed. Statistical significance will be set at \(P < 0.05\). All values will be expressed as mean ± standard deviation or median ± range.

A multivariate analysis of variance (MANOVA) will be used on our primary outcome (i.e., exercise tolerance) and secondary outcomes (i.e., quality of life, fatigue, physical activity level, strength, fatigability, body composition, cachexia, physical performance, and respiratory function) to protect against Type I errors arising from multiple comparisons. A two-way mixed-design ANOVA will be used (group [lung cancer – colorectal cancer – breast cancer] × time [first visit – second visit – third visit]). Finally, if a significant difference is found, a multiple-comparison analysis will be performed using an appropriate post-hoc test.

Finally, interaction between specific variables will be tested with Pearson’s correlation coefficients (\(r^2\)). For example, we plan to test the possible correlation between subjective and objective fatigue, or between exercise tolerance/quality of life and body composition.

Ethics and Dissemination
This prospective three-armed cohort study has been approved by the national ethics committee (2019-A00848-49). All subjects gave written informed consent in accordance with the Declaration of Helsinki. Any amendment to the protocol will require the formal modification and approval by the same local ethics committee that approved the study prior to implementation and will be described transparently in subsequent reports. This study is also registered at ClinicalTrials.gov (NCT03956641, first posted in May 2019). Patient recruitment and data collection began in September 2019 and are being conducted at Paul Strauss Center Strasbourg and Cancer Institute Strasbourg Europe, Strasbourg, France.

DISCUSSION
The aim of the PROTECT-01 study will be to investigate the evolution of the physical status, from diagnosis to the end of first-line treatment, of patients with one of the three most common cancers, namely lung, breast, and colorectal (51). Therefore, the present investigation will identify the nature and severity of maladaptation related to exercise intolerance in these three types of cancer. Our results should contribute to identifying
the needs of each group of patients and to determining the most valuable exercise interventions to prescribe (i.e., modality, intensity, etc.) in order to counteract major disease-related physical and physiological alterations.

Rationale and Novelty
Although the consequences of the disease and the associated treatments on physical and physiological function are not completely unknown, the present study protocol is original in several aspects. First, this study is not dedicated to one specific physiological function or organ but is instead focused on assessments of respiratory and muscular functions, cachexia, muscle fatigue, exercise tolerance, perceived fatigue, and quality of life, in order to better prioritize what to target in future exercise prescriptions (e.g., resistance training). Importantly, the relationship between objective (i.e., neuromuscular) and subjective (i.e., perceived) measures of fatigue is insightful (71, 72) and has been clearly identified as a priority (73). Moreover, objective measurements of fatigue are requisite to investigate mechanistically cancer-related fatigue, while the majority of CRF research is, to date, questionnaire-based (2, 74–78). Indeed, while CRF is the major symptom of the disease, which can last despite clinical remission (15), muscle fatigue has not been as extensively investigated in cancer as it has been in other diseases associated with chronic fatigue, such as multiple sclerosis (62, 79) or heart failure (80).

Another strength of the “global” approach of our study is the concomitant interest in CRF and cachexia, two major symptoms (81) that may have substantial interaction (5, 30–32), as suggested in the vicious cycle presented in Figure 1. CRF has been shown to promote inactivity (17, 18), leading to muscle deconditioning (19–23) mainly characterized by a loss in muscle force and mass (4). These rapid muscle alterations are in turn increasing fatigue and fueling this vicious cycle (31). The potential link between these two symptoms seems strong but requires further investigation (72). The PROTECT-01 cohort study is designed to investigate this relationship between CRF and cancer cachexia in cancer patients using repeated measures from diagnosis to the end of first-line treatment. Moreover, the combination of iso-time and iso-status measurements between the three cancers investigated (i.e., after 8 weeks of treatment and after the first-line treatment, respectively) will be important in comparing the specific maladaptation associated with the type of cancer investigated despite differences in treatment durations. The iso-time comparison will be performed to identify the rate of change for each physical and physiological parameter assessed, while the iso-status comparison will be performed to compare the consequences of first-line treatment on our series of assessments across the three cancers investigated.

Expected Impact and Perspectives
The PROTECT-01 study is expected to bring to light the nature and severity of maladaptation related to exercise intolerance in the three most common cancers. This descriptive and comprehensive study is requisite in order to design interventional research projects with exercise interventions to target a major symptom or maladaptation observed. Importantly, if “exercise is medicine” (82), it is essential to note that it works, to make an analogy, like a pill. Exercise needs to be prescribed with the appropriate “active principle” (i.e., exercise modality) and “dose” (i.e., exercise intensity and duration) to be effective (83). For example, the prevalence of cachexia is high (∼50%) and greater in lung or colorectal cancers compared to breast cancer (3). Therefore, resistance training may be of particular interest for lung or colorectal cancer patients, while breast cancer patients may get more health benefits from aerobic exercise to focus on cardiovascular outcomes (9, 50). However, it should be emphasized that this speculation is done without a global and comparative approach, which is needed for such a conclusion. The goal of the PROTECT-01 cohort study will be to provide this approach and initiate future randomized control trials with specific exercise interventions for various cancer patients according to their circumstances. In a context where the suggestion of a unique exercise modality (i.e., resistance, aerobic, or combined training) as the best strategy for all cancer patients may not be convincing (84), we and others (49, 73, 83) believe that tailored exercise interventions are necessary to optimize cancer patient health outcomes and substantially improve their quality of life.

Methodological Considerations
In order to assess the evolution of the physical status of the patients, this study will require multiple visits from diagnosis to the end of first-line treatment. Thus, at the first visit, newly diagnosed cancer patients will be tested before starting any treatment, indicating that we will be able to assess effects of the disease at this time. However, subsequent visits will be performed during and at the end of first-line treatment, indicating that our measurements will assess the consequences of both the disease and the associated side effects of the treatment (18, 85, 86). Therefore, it will not be possible to isolate the effects of the disease vs. the treatments on our measures in this study. Regardless, it is more important to characterize the combined effect of these two stressors on the physical function of cancer patients, as we actually want to counteract them simultaneously in order to ultimately improve the survival and quality of life of these patients.

Cancer is a complex disease with various stages and a multitude of available antineoplastic treatments. As a consequence, the patient population can be heterogeneous. In order to avoid high variability between our participants, we decided to limit our inclusion criteria (Table 1) to the most frequent stages encountered at diagnosis in our clinical setup. There are still substantial differences in the treatment between participants; however, what matters in our experimental context is to assess the potential maladaptations of the disease with the treatment that is supposed to be the most optimal to their individual condition. This approach is driven by the end goal of our research projects, which is to determine the best-tailored exercise interventions for cancer patients, and not to assess the net efficacy of one specific treatment.

Finally, the physical activity level will likely differ between patients as well as individually throughout the
experiment. As we will be able to control for this variable using the GPAQ score, this will be a great opportunity to provide preliminary insights on the effect of physical activity on our measurements prior to interventional training studies.

ETHICS STATEMENT

The protocol was approved by the French Ethics Committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III, number ID RCB: 2019-A00848-49). All subjects gave written informed consent in accordance with the Declaration of Helsinki.

AUTHOR CONTRIBUTIONS

JM, EH, RS, TP, MD, CB, MB, HC, PC, CF, MK-W, AB, SD, FE, XP, TH, and AP contributed to the study design as well as writing and/or editing the manuscript and approved the final version of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Institut de Cancérologie Strasbourg Europe. This work has been published under the framework of the IdEx Unistra supported by the investments for the future program of the French Government.

ACKNOWLEDGMENTS

We thank Valérie Sartori, Alexandre Bernard, Manon Voegelin, Elodie Magisson, Dorette Goetz, and Anais Robert from the Clinical Research Department for their administrative and organizational support. We also want to greatly thank Nadine Adam for her very helpful support with English revisions.

REFERENCES

1. Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. (2002) 12:424–8. doi: 10.1136/ijgc-00009577-200209000-00002
2. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet Lond Engl. (2003) 362:640–50. doi: 10.1016/S0140-6736(03)14186-4
3. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Sarcopenia Muscle. (2017) 8:623. doi: 10.1002/med.21299
4. Prigerson HG, Bao Y, Shah MA, Paulk ME, Leblanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. (2015) 1:778–84. doi: 10.1001/jamaoncol.2015.2378
5. Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Muscle mass and as target to reduce fatigue in patients with advanced cancer. J Cachexia Sarcopenia Muscle. (2018) 9:4105. doi: 10.1002/jcn.23606
6. Prigerson HG, Bao Y, Shah MA, Paulk ME, Leblanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. (2015) 1:778–84. doi: 10.1001/jamaoncol.2015.2378
7. Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French comprehensive cancer centres. Br J Cancer. (2010) 102:966–71. doi: 10.1038/sj.bjc.6605578
8. Dudgeon DJ, Kristjansson L, Sloan JA, Lertzman M, Clement K. Dysfunction in cancer patients: prevalence and associated factors. J Pain Symptom Manage. (2001) 21:95–102. doi: 10.1016/S0885-8929(00)00258-X
9. Quinten C, Martinelli F, Coens C, Sprangers MAG, Ringash J, Gotay C, et al. A global analysis of multivariate data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. (2014) 120:302–11. doi: 10.1002/cncr.28382
10. Roaof A, Yakoub S, Asaad Y, Hadithi TA. Quality of life among cancer patients treated with chemotherapy or radiotherapy in erbil city an evaluation study. Cancer Clin Oncol. (2015) 4:19. doi: 10.5539/cco.v4n1p19
11. Enoka RM, Duchateau J. Translating fatigue to human performance. Med Sci Sports Exerc. (2016) 48:2228–38. doi: 10.1249/MSS.0000000000000929
12. Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. (2004) 91:822–28. doi: 10.1038/sj.bjc.6602012
13. Cella D, Davis K, Breitbart W, Curt G. Fatigue Coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. (2001) 19:3385–91. doi: 10.1200/JCO.2001.19.14.3385
14. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist. (2000) 5:533–60. doi: 10.1634/theoncologist.5-5-353
15. Ferruoli E, Skipworth RJE, Hendry P, Scott A, Stensteth J, Dahele M, et al. Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J Pain Symptom Manage. (2012) 43:1025–35. doi: 10.1016/j.jpainsymman.2011.06.013
16. Christensen JF, Jones LW, Andersen JL, Daugaard G, Rorth M, Hojman P. Muscle dysfunction in cancer patients. Ann Oncol. (2014) 25:947–58. doi: 10.1093/annonc/mdt151
17. Brioche T, Pagano AF, Py G, Chopard A. Muscle wasting and aging: experimental models, fatty infiltrations, and prevention. Mol Aspects Med. (2016) 50:56–87. doi: 10.1016/j.mam.2016.04.006
18. Bodine SC. Disuse-induced muscle wasting. Int J Biochem Cell Biol. (2013) 45:2200–8. doi: 10.1016/j.biocel.2013.06.011
19. Chopard A, Hillock S, Jasmin BJ. Molecular events and signalling pathways involved in skeletal muscle disuse-induced atrophy and the impact of countermeasures. J Cell Mol Med. (2009) 13:3032–50. doi: 10.1111/j.1582-4934.2009.00864.x
20. Demangel R, Treffel L, Py G, Brioche T, Pagano AF, Bareille M-P, et al. Early structural and functional signature of 3-day human skeletal muscle disuse using the dry immersion model. J Physiol. (2017) 595:4301–15. doi: 10.1113/jp273895
21. Oikawa SY, Holloway TM, Phillips SM. The impact of step reduction on muscle health in aging: protein and exercise as countermeasures. Front Nutr. (2019) 6:75. doi: 10.3389/fnut.2019.00075
22. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr Edibh Scotl. (2008) 27:793–99. doi: 10.1016/j.clinu.2008.06.013
23. Madeddu C, Mantovani G, Gramignano G, Astara G, Macciò A. Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. Future Oncol Lond Engl. (2015) 11:2697–710. doi: 10.2217/fon.15.195
26. Macciò A, Busquets S, Madeddu C, Argilés JM. Editorial: biological mechanism-based and patient-centered management of cancer-related symptoms and syndromes. Front Physiol. (2018) 9:1819. doi: 10.3389/fphys.2018.01819.

27. Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. (2013) 4:173–8. doi: 10.1007/s13539-013-0105-y.

28. Martin L, Senesse P, Gioulbasian I, Antoun S, Bozzetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. (2015) 33:90–9. doi: 10.1200/JCO.2014.56.1894.

29. Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM. One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA. Drug Context. (2014) 3:211265. doi: 10.7573/dic.2013.05.018.

30. Ryan JL, Carroll JK, Ryan EP, Mustian KM, Fiscella K, Morrow GR. Mechanisms of cancer-related fatigue. Oncologist. (2007) 12:22–34. doi: 10.1634/theoncologist.12-S1-22.

31. Powers SK, Lynch GS, Murphy KT, Reid MB, Zijdewind I. Disease-induced skeletal muscle atrophy and fatigue. Med Sci Sports Exerc. (2016) 48:2307–19. doi: 10.1249/MSS.0000000000000975.

32. Roberts BM, Frye GS, Ahn B, Ferreira LF, Judge AR. Cancer cachexia decreases specific force and accelerates fatigue in limb muscle. Biochem Biophys Res Commun. (2013) 435:488–92. doi: 10.1016/j.bbrc.2013.05.018.

33. Kelley GA, Kelley KS. Exercise and cancer-related fatigue in adults: a systematic review of previous systematic reviews with meta-analyses. BMC Cancer. (2017) 17:693. doi: 10.1186/s12885-017-3687-5.

34. Mustian KM, Peppone L, Darling TV, Palesh O, Heckler CE, Morrow GR. Mechanisms of cancer-related fatigue. Oncologist. (2007) 12:22–34. doi: 10.1634/theoncologist.12-S1-22.

35. CDC. The PROTECT -01 Cohort Study Protocol. 2013.

36. Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and cancer. Acta Otolaryngol (Stockh). (2019) 139:383–7. doi: 10.1080/03009731.2019.1660795.

37. Farkas J, von Haehling S, Kalantar-Zadeh K, Morley JE, Anker SD, Lainscak M. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle. (2013) 4:173–8. doi: 10.1007/s13539-013-0105-y.

38. van der Leeden M, Huismans RJ, Geleijn E, de Rooij M, Konings IR, Buffart LM, et al. Tailoring exercise interventions to comorbidities and treatment-induced adverse effects in patients with early stage breast cancer undergoing chemotherapy: a framework to support clinical decisions. Disabil Rehabil. (2018) 40:486–96. doi: 10.1080/09638288.2016.1260647.

39. Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV, et al. The risk of heart failure and other cardiovascular hospitalizations after early stage breast cancer: a matched cohort study. J Natl Cancer Inst. (2019) 111:854–62. doi: 10.1093/jnci/djy218.

40. Ferrarotto V, Feray J, Soejornmataram I, Stiegel RL, Torle JA. JEM. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.1002/caac.21492.

41. Butt Z, Lai J, Rao D, Heinemann AW, Bill A, Cella D. Measurement of fatigue in cancer, stroke, and HIV using the functional assessment of chronic illness therapy–fatigue (FACIT-F) scale. J Psychosom Res. (2013) 74:64–8. doi: 10.1016/j.jpsychores.2012.10.011.

42. Armstrong T, Bull F. Development of the World Health Organization Global Physical Activity Questionnaire (GPAQ). J Public Health. (2006) 14:66–70. doi: 10.1093/ije/dyi004.2010-0024-x.

43. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. (1993) 85:356–7. doi: 10.1093/jnci/85.5.356.

44. Bosy-Westphal O, Schatz B, Later W, Kehayas JJ, Gallagher D, Müller MJ. What makes a BIA equation unique? Validity of eight-electrode multifrequency BIA to estimate body composition in a healthy adult population. Eur J Clin Nutr. (2013) 67:514–21. doi: 10.1038/ejcn.2012.160.

45. Benavides-Rodriguez L, Garcia-Hermoso A, Rodrigues-Bezerra D, Izquierdo M, Correa-Bautista JE, Ramirez-Velez R. Relationship between handgrip strength and muscle mass in female survivors of breast cancer: a mediation analysis. Nutrients. (2017) 9:695. doi: 10.3390/nu9070695.

46. Freitag N, Weber PD, Sanders TC, Schulz H, Bloch W, Schumann M. High-intensity interval training and hyperoxia during chemotherapy. Medicine (Baltimore). (2018) 97:e11068. doi: 10.1097/MD.0000000000011068.

47. Lundberg M, Dickinson A, Nikander P, Orell H, Mäkitie A. Low-phase angle intolerance in cancer and the role of exercise therapy to reverse it. Acta Otolaryngol (Stockh). (2019) 139:383–7. doi: 10.1080/03009731.2019.1566779.

48. Ferrario C, Cosentino D, Lines H, Cross T, Dixon S. Factors influencing the length of stay for breast cancer patients undergoing mastectomy: an independent sector perspective. Eur J Surg Oncol. (2016) 42:523. doi: 10.1016/j.ejso.2016.02.094.

49. Mathiowetz V. Grip and pinch strength measurements. In: Amundsen LR, ed. Muscle Strength Testing: Instrumented and Non-Instrumented Systems. New York, NY: Churchill Livingstone (1990). p. 163–7.

50. Fess EE. Grip strength. In: American Society of Hand Therapists, ed. Clinical Assessment Recommendations. 2nd ed. Garner, NC: American Society of Hand Therapists (1992). p. 41–5.

51. Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev. (2001) 81:1725–89. doi: 10.1152/physrev.2001.81.4.1725.

52. Freire AN, Guerra RO, Albarado B, Guralnik JM, Zunzunegui MV. Validity and reliability of the short physical performance battery in two diverse older adult populations in Quebec and Brazil. J Aging Health. (2012) 24:863–78. doi: 10.1177/0898264312438551.

53. Fess EE. Grip strength. In: American Society of Hand Therapists, ed. Clinical Assessment Recommendations. 2nd ed. Garner, NC: American Society of Hand Therapists (1992). p. 41–5.

54. Ferrario C, Cosentino D, Lines H, Cross T, Dixon S. Factors influencing the length of stay for breast cancer patients undergoing mastectomy: an independent sector perspective. Eur J Surg Oncol. (2016) 42:523. doi: 10.1016/j.ejso.2016.02.094.

55. Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Oster G, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and values of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. (2000) 55:M212–31. doi: 10.1093/gerona/55.4.M212.

56. ATS C. Standee on Profficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. (2002) 166:111–7. doi: 10.1164/ajrccm.166.1.a11102.

57. Jones LW, Hornby WE, Goetzinger A, Forbes LM, Sherrard EL, Quist M, et al. Prognostic significance of functional capacity and exercise behavior
in patients with metastatic non-small cell lung cancer. *Lung Cancer.* (2012) 76:248–52. doi: 10.1016/j.lungcan.2011.10.009

67. Demers C, McKeilve RS, Negassa A, Yusuf S, RESOLVD Pilot Study Investigators. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. *Am Heart J.* (2001) 142:698–703. doi: 10.1067/mhj.2001.118468

68. Chary J, Biswas T. How to calculate sample size for different study designs in medical research? *Indian J Psychol Med.* (2013) 35:121–6. doi: 10.4103/0253-7176.116232

69. Granger CL, Holland AE, Gordon IR, Denehy L. Minimal important difference of the 6-minute walk distance in lung cancer. *Chron Respir Dis.* (2015) 12:146–54. doi: 10.1177/1479972315575715

70. Camarri B, Eastwood PR, Cecins NM, Thompson PJ, Jenkins S. Six minute walk distance in healthy subjects aged 55-75 years. *Respir Med.* (2006) 100:658–65. doi: 10.1016/j.rmed.2005.08.003

71. Veni T, Boyas S, Beaune B, Bourgeois H, Rahmani A, Landry S, et al. Handgrip fatiguing exercise can provide objective assessment of cancer-related fatigue: a pilot study. *Support Care Cancer.* (2019) 27:229–38. doi: 10.1007/s00520-018-4320-0

72. Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, et al. Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. *J Cachexia Sarcopenia Muscle.* (2010) 1:177–85. doi: 10.1007/s13539-010-0016-0

73. Twomey R, Martin T, Temesi J, Culos-Reed SN, Millet GY. Tailored exercise interventions to reduce fatigue in cancer survivors: study protocol of a randomized controlled trial. *BMC Cancer.* (2018) 18:757. doi: 10.1186/s12885-018-4668-z

74. Abrahams HJ, Gielissen MF, Schmits IC, Verhagen CA, Rozendaal MM, Knoop H. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. *Ann Oncol.* (2016) 27:965–74. doi: 10.1093/annonc/mdw099

75. Zick SM, Sen A, Wyatt GK, Murphy SL, Arnedt JT, Harris RE. Investigation of 2 types of self-administered acupressure for persistent cancer-related fatigue in breast cancer survivors: a randomized clinical trial. *JAMA Oncol.* (2016) 2:1470–6. doi: 10.1001/jamaoncol.2016.1867

76. Molassiotis A, Bardy J, Finnegan-John J, Mackereth P, Ryder DW, Filshie J, et al. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. *J Clin Oncol Off J Am Soc Clin Oncol.* (2012) 30:4470–6. doi: 10.1200/JCO.2012.41.6222

77. Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. *JAMA Oncol.* (2017) 3:961–8. doi: 10.1001/jamaoncol.2016.6914

78. Storey DJ, McLaren DB, Atkinson MA, Butcher I, Frew LC, Smyth JE, et al. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. *Ann Oncol.* (2012) 23:1542–9. doi: 10.1093/annonc/mdr447

79. Steens A, Heersma DJ, Maurits NM, Renken RJ, Zijdewind I. Mechanisms underlying muscle fatigue differ between multiple sclerosis patients and controls: a combined electrophysiological and neuroimaging study. *NeuroImage.* (2012) 59:3110–8. doi: 10.1016/j.neuroimage.2011.11.038

80. Harridge SD, Magnusson G, Gordon A. Skeletal muscle contractile characteristics and fatigue resistance in patients with chronic heart failure. *Eur Heart J.* (1996) 17:896–901. doi: 10.1093/oxfordjournals.eurheart.a014971

81. Stewart GD, Skipworth RJ, Fearon KCH. Cancer cachexia and fatigue. *Clin Med Lond Engl.* (2006) 6:140–3. doi: 10.7861/clinmedicine.6-2-140

82. Lobelo F, Stoutenberg M, Hutber A. The exercise is medicine global health initiative: a 2014 update. *Br J Sports Med.* (2014) 48:1627–33. doi: 10.1136/bjsports-2013-093080

83. Lucia A, Earnest C, Pérez M. Cancer-related fatigue: can exercise physiology assist oncologists? *Lancet Oncol.* (2003) 4:616–25. doi: 10.1016/S1470-2045(03)01221-X

84. Stene GB, Helbostad JL, Balstad TR, Ripphagen I, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment—a systematic review. *Crit Rev Oncol Hematol.* (2013) 88:573–93. doi: 10.1016/j.critrevonc.2013.07.001

85. Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. *J Natl Cancer Inst Monogr.* (2001) 30:135–42. doi: 10.1093/oxfordjournals.jncimonographs.a003451

86. Mustian KM, Sprod LK, Palesh OG, Pepitone LJ, Janselins MC, Mohile SG, et al. Exercise for the management of side effects and quality of life among cancer survivors. *Carr Sports Med Rep.* (2009) 8:325–30. doi: 10.1249/JSR.0b013e3181c22324

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Mallard, Hucteau, Schott, Petit, Demarchi, Belletier, Ben Abdelghani, Carinato, Chiappa, Fischbach, Kalish-Weindling, Dufour, Favret, Pivot, Hureau and Pagano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.